Breaking News

XBiotech In-Licenses Strox Biopharma Technology

April 4, 2014

Will be used to enhance infectious disease development program

XBiotech has in-licensed Strox Biopharmaceuticals technology relating to antibody therapies for methicillin resistant staphylococcus aureus (MRSA). The technology will be used to enhance XBiotech's infectious disease product development program, and includes both issued and pending patents for antibody technologies for either prevention or therapeutic intervention for resistant and life threatening infections. Strox will receive an upfront cash payment and royalties on sales. XBiotech will be responsible for costs and patent prosecution and maintenance. 
XBiotech's True Human antibody therapy for staph infections is derived from an antibody cloned from a natural human immune response and is designed to enable the patient's immune system to naturally, safely, and effectively eradicate the S. aureus infection.
XBiotech's chief executive officer, John Simard, said, "This is a case where the advantages of true human antibodies represent a quantum advance that goes well beyond safety. Identifying a precise antibody among the donor population that neutralizes a pathogen allows for the development of targeted anti-infective therapy with a potential for safety and efficacy unlike anything that has been marketed to date. We are very excited about what this therapy represents. And the intellectual property we have now acquired helps to expand the possibilities for our development efforts in this very important area of medicine."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important